Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oneness Biotech CoROCO:4743 -3.38%59 Current Ratio is 11.81 as of Dec. 2025, which is 70% below its 10-year median of 39.67. GuruFocus rates ROCO:4743 with a GF Score™ of 59/100 and a GF Value™ of NT$81.63 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Oneness Biotech Co ranks better than 81.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Oneness Biotech Co's current ratio for the quarter that ended in Dec. 2025 was 11.81.
Oneness Biotech Co has a current ratio of 11.81. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Oneness Biotech Co's Current Ratio or its related term are showing as below:
ROCO:4743'
s Current Ratio Range Over the Past 10 Years
Min: 11.81 Med: 39.67 Max: 58.15
Current: 11.81
During the past 13 years, Oneness Biotech Co's highest Current Ratio was 58.15. The lowest was 11.81. And the median was 39.67.
ROCO:4743's Current Ratio is ranked better than 81.64% of 1411
companies
in the Biotechnology industry
Industry Median: 3.89
vs ROCO:4743: 11.81
Oneness Biotech Co (ROCO:4743) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Oneness Biotech Co Current Ratio Related Terms
Oneness Biotech Co Current Ratio Historical Data
* Premium members only.
The historical data trend for Oneness Biotech Co's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4743 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Oneness Biotech Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oneness Biotech Co (ROCO:4743) has a Current Ratio of 11.81 as of Dec. 2025. This is 70% below median its historical median of 39.67. Over the past decade, Oneness Biotech Co's Current Ratio has ranged from 11.81 to 58.15. According to the industry distribution chart, Oneness Biotech Co ranks #259 out of 1411 companies in the Biotechnology industry, placing it in the top 18.4%.
Is Oneness Biotech Co's Current Ratio too high?
Oneness Biotech Co's current Current Ratio of 11.81 is 70% below median its 10-year median of 39.67. Over the past 10 years, this metric has ranged from a low of 11.81 to a high of 58.15. The Biotechnology industry median Current Ratio is 3.89. Oneness Biotech Co's value of 11.81 is 203.6% above this industry median. Based on the distribution chart, Oneness Biotech Co ranks #259 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oneness Biotech Co has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #259 out of 1411 companies for Current Ratio. This places Oneness Biotech Co in the top 18% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Oneness Biotech Co's value of 11.81 is 203.6% above this benchmark. Historically, Oneness Biotech Co's own Current Ratio has ranged from 11.81 to 58.15 over the past decade. While the company's 10-year median is 39.67 vs. the industry median of 3.89, Oneness Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oneness Biotech Co's current Current Ratio of 11.81 is 203.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oneness Biotech Co's current Current Ratio is 11.81, which is 70% below median its own 10-year median of 39.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Oneness Biotech Co (ROCO:4743) is currently considered Possible Value Trap. The stock's GF Value™ is NT$81.63, compared to a current price of NT$48.60 — trading 40.5% below its estimated fair value. The current Current Ratio is 11.81, which is 70% below median its 10-year median of 39.67 and 203.6% above the Biotechnology industry median of 3.89. Oneness Biotech Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Oneness Biotech Co (ROCO:4743), the current Current Ratio is 11.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (ROCO:4743) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of NT$48.60 is trading 40.5% below its estimated GF Value™ of NT$81.63.
GuruFocus considers Oneness Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4743:
Current Ratio: 11.81 (70% below median its 10-year median of 39.67)
GF Value™: NT$81.63 vs. price of NT$48.60 (40.5% below fair value)
Industry Position: 203.6% above the Biotechnology median (#259 of 1411)
No single metric tells the full story. See the ROCO:4743 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
59GF Score
Get the complete analysis for ROCO:4743
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4743 has been successfully added to your 
